Abstract
Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. Conventional pathology approaches have not identified a precise predictive biomarker for Eribulin. We performed qmIF on pre-treatment tissue from 11 patients (6 TNBC, 5 HGSOC) treated with Eribulin-LF. T-lymphocytes were the dominant immune-subset in TME, with higher levels detected in stroma vs tumor (9% vs 2%). Greater density of CD3+ (p = 0.01) and CD3 + CD8+ (p = 0.03) cells and closer proximity between CD3 + CD8+ and tumor cells was observed in the patients with disease control (PR + SD) vs. progressive disease. QmIF identified an association between TIL infiltration and Eribulin-LF sensitivity, which should be evaluated further in prospective studies.
Original language | English |
---|---|
Pages (from-to) | 466-472 |
Number of pages | 7 |
Journal | Cancer Investigation |
Volume | 39 |
Issue number | 6-7 |
DOIs | |
State | Published - 2021 |
Externally published | Yes |
Keywords
- EMT
- Eribulin
- Eribulin-LF
- Metastatic breast cancer
- metastatic ovarian cancer
- phase I clinical trial
- quantitative multiplex immunofluorescence
- tumor immunobiology
- tumor microenvironment